New European Program Targets Novel Antibiotics
Innovative Medicines Initiative will develop novel antibiotics against gram-negative pathogens in a project called ENABLE.
Over 30 European universities and companies, led by GlaxoSmithKline and Uppsala University, are participating in a six-year program funded by the Innovative Medicines Initiative (IMI) to develop novel antibiotics against gram-negative pathogens in a project called ENABLE (European Gram Negative Antibacterial Engine).
The IMI, a research partnership between the European Commission and major pharmaceutical companies (through EFPIA, the European Federation of Pharmaceutical Industries and Associations), has launched New Drugs for Bad Bugs (ND4BB), a series of projects that targets the challenges in the development and effective use of novel antibiotics.
The ENABLE project, the third within the ND4BB series, spans 13 countries and brings together 32 partners with the goal to establish an anti-bacterial drug discovery platform for the progression of research programs through discovery and Phase I clinical trials. A preliminary portfolio of programs will be expanded through open calls outside the consortium to create a full development pipeline, with the goal to deliver at least one novel anti-bacterial candidate against gram-negative infections into phase II clinical trials by 2019.
Source: Innovative Medicines Initiative
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.
